G1 Therapeutics, Inc. (NASDAQ:GTHX) has a beta value of 2.43 and has seen 1,105,626 shares traded in the last trading session. The company, currently valued at $759.4 Million, closed the last trade at $19.96 per share which meant it gained $1.18 on the day or 6.28% during that session. The GTHX stock price is -33.72% off its 52-week high price of $26.69 and 55.91% above the 52-week low of $8.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 Million shares traded. The 3-month trading volume is 1.25 Million shares.
The consensus among analysts is that G1 Therapeutics, Inc. (GTHX) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 8 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.87.
G1 Therapeutics, Inc. (NASDAQ:GTHX) trade information
Sporting 6.28% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jan 12 when the GTHX stock price touched $20.17- or saw a rise of 1.04%. Year-to-date, G1 Therapeutics, Inc. shares have moved 10.95%, while the 5-day performance has seen it change 12.26%. Over the past 30 days, the shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) have changed 5.16%. Short interest in the company has seen 7.36 Million shares shorted with days to cover at 5.89.
Wall Street analysts have a consensus price target for the stock at $50, which means that the shares’ value could jump 150.5% from current levels. The projected low price target is $21 while the price target rests at a high of $82. In that case, then, we find that the current price level is +310.82% off the targeted high while a plunge would see the stock lose 5.21% from current levels.
G1 Therapeutics, Inc. (GTHX) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -65.6% over the past 5 years. Earnings growth for 2021 is a modest -27.6%.
G1 Therapeutics, Inc. (NASDAQ:GTHX)’s Major holders
Insiders own 10.4% of the company shares, while shares held by institutions stand at 90.9% with a share float percentage of 101.45%. Investors are also buoyed by the number of investors in a company, with G1 Therapeutics, Inc. having a total of 193 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 4.29 Million shares worth more than $49.55 Million. As of September 29, 2020, FMR, LLC held 11.28% of shares outstanding.
The other major institutional holder is Wellington Management Company, LLP, with the holding of over 2.99 Million shares as of September 29, 2020. The firm’s total holdings are worth over $34.5 Million and represent 7.85% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and JP Morgan Small Cap Growth Fund. As of December 30, 2020, the former fund manager holds about 5.07% shares in the company for having 1929978 shares of worth $34.72 Million while later fund manager owns 1.04 Million shares of worth $18.94 Million as of November 29, 2020, which makes it owner of about 2.73% of company’s outstanding stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.